CN105596420A - Application of salviae miltiorrhizae and panax notoginseng composition and preparation method - Google Patents
Application of salviae miltiorrhizae and panax notoginseng composition and preparation method Download PDFInfo
- Publication number
- CN105596420A CN105596420A CN201610163942.0A CN201610163942A CN105596420A CN 105596420 A CN105596420 A CN 105596420A CN 201610163942 A CN201610163942 A CN 201610163942A CN 105596420 A CN105596420 A CN 105596420A
- Authority
- CN
- China
- Prior art keywords
- ethanol
- thick paste
- relative density
- sage root
- pseudo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 59
- 238000002360 preparation method Methods 0.000 title claims abstract description 53
- 235000003143 Panax notoginseng Nutrition 0.000 title claims abstract description 31
- 241000180649 Panax notoginseng Species 0.000 title claims abstract description 31
- 239000003814 drug Substances 0.000 claims abstract description 52
- 239000000843 powder Substances 0.000 claims abstract description 48
- 239000000284 extract Substances 0.000 claims abstract description 29
- 229940079593 drug Drugs 0.000 claims abstract description 25
- 239000000463 material Substances 0.000 claims abstract description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 129
- 240000007164 Salvia officinalis Species 0.000 claims description 82
- 235000005412 red sage Nutrition 0.000 claims description 82
- 244000131316 Panax pseudoginseng Species 0.000 claims description 69
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims description 66
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 39
- 238000000605 extraction Methods 0.000 claims description 37
- 238000010992 reflux Methods 0.000 claims description 35
- 239000000469 ethanolic extract Substances 0.000 claims description 29
- 230000036772 blood pressure Effects 0.000 claims description 28
- 238000010438 heat treatment Methods 0.000 claims description 27
- 239000006286 aqueous extract Substances 0.000 claims description 18
- 239000011347 resin Substances 0.000 claims description 14
- 229920005989 resin Polymers 0.000 claims description 14
- 239000002250 absorbent Substances 0.000 claims description 11
- 230000002745 absorbent Effects 0.000 claims description 11
- 239000002775 capsule Substances 0.000 claims description 11
- 239000006210 lotion Substances 0.000 claims description 11
- 235000012054 meals Nutrition 0.000 claims description 9
- 239000008188 pellet Substances 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 8
- 238000001291 vacuum drying Methods 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 6
- 238000005507 spraying Methods 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 239000007901 soft capsule Substances 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 238000009495 sugar coating Methods 0.000 claims description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 239000003463 adsorbent Substances 0.000 claims description 3
- 238000007605 air drying Methods 0.000 claims description 3
- 239000007888 film coating Substances 0.000 claims description 3
- 238000009501 film coating Methods 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 29
- 230000003276 anti-hypertensive effect Effects 0.000 abstract description 10
- 241000196324 Embryophyta Species 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 230000008901 benefit Effects 0.000 abstract description 2
- 238000002156 mixing Methods 0.000 abstract description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 abstract 2
- 230000029087 digestion Effects 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 28
- 239000008280 blood Substances 0.000 description 28
- 239000000243 solution Substances 0.000 description 19
- 239000002253 acid Substances 0.000 description 16
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 12
- 239000004615 ingredient Substances 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 9
- 230000017531 blood circulation Effects 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 8
- 229930183118 Tanshinone Natural products 0.000 description 7
- 239000000470 constituent Substances 0.000 description 7
- 206010020772 Hypertension Diseases 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 208000002173 dizziness Diseases 0.000 description 4
- 230000005906 menstruation Effects 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 235000002789 Panax ginseng Nutrition 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 235000008434 ginseng Nutrition 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 230000001077 hypotensive effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- -1 sieve Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 description 2
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 240000008574 Capsicum frutescens Species 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- GVKKJJOMQCNPGB-JTQLQIEISA-N Cryptotanshinone Chemical compound O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1[C@@H](C)CO2 GVKKJJOMQCNPGB-JTQLQIEISA-N 0.000 description 2
- GVKKJJOMQCNPGB-UHFFFAOYSA-N Cryptotanshinone Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)CO2 GVKKJJOMQCNPGB-UHFFFAOYSA-N 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 206010013954 Dysphoria Diseases 0.000 description 2
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229930189092 Notoginsenoside Natural products 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000003727 cerebral blood flow Effects 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 208000021822 hypotensive Diseases 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000003821 menstrual periods Effects 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- QBLFZIBJXUQVRF-UHFFFAOYSA-N (4-bromophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Br)C=C1 QBLFZIBJXUQVRF-UHFFFAOYSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 1
- RHAXKFFKGZJUOE-UHFFFAOYSA-N 7-acetyl-6-ethyl-3,5,8-trihydroxy-9,10-dioxoanthracene-1,2-dicarboxylic acid Chemical compound O=C1C2=CC(O)=C(C(O)=O)C(C(O)=O)=C2C(=O)C2=C1C(O)=C(CC)C(C(C)=O)=C2O RHAXKFFKGZJUOE-UHFFFAOYSA-N 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 240000004859 Gamochaeta purpurea Species 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- QURCVMIEKCOAJU-HWKANZROSA-N Isoferulic acid Natural products COC1=CC=C(\C=C\C(O)=O)C=C1O QURCVMIEKCOAJU-HWKANZROSA-N 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000000157 blood function Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000001964 calcium overload Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- VPLLTGLLUHLIHA-UHFFFAOYSA-N dicyclohexyl(phenyl)phosphane Chemical compound C1CCCCC1P(C=1C=CC=CC=1)C1CCCCC1 VPLLTGLLUHLIHA-UHFFFAOYSA-N 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 1
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 1
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229930195208 isotanshinone Natural products 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- XHALVRQBZGZHFE-KRWDZBQOSA-N methyl rosmarinate Natural products COC(=O)[C@H](Cc1ccc(O)c(O)c1)OC(=O)C=Cc2ccc(O)c(O)c2 XHALVRQBZGZHFE-KRWDZBQOSA-N 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229960005425 nitrendipine Drugs 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- LLPWNQMSUYAGQI-OOSPGMBYSA-N notoginsenoside R1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)CO2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O LLPWNQMSUYAGQI-OOSPGMBYSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229960003371 protocatechualdehyde Drugs 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 description 1
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 description 1
- XHALVRQBZGZHFE-UHFFFAOYSA-N rosmarinic acid methyl ester Natural products C=1C=C(O)C(O)=CC=1C=CC(=O)OC(C(=O)OC)CC1=CC=C(O)C(O)=C1 XHALVRQBZGZHFE-UHFFFAOYSA-N 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- CMXPERZAMAQXSF-UHFFFAOYSA-M sodium;1,4-bis(2-ethylhexoxy)-1,4-dioxobutane-2-sulfonate;1,8-dihydroxyanthracene-9,10-dione Chemical compound [Na+].O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O.CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC CMXPERZAMAQXSF-UHFFFAOYSA-M 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 239000002550 vasoactive agent Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an application of a salviae miltiorrhizae and panax notoginseng composition and a preparation method and provides an application of the salviae miltiorrhizae and panax notoginseng composition in preparation of antihypertensive medicines and a preparation method of the salviae miltiorrhizae and panax notoginseng composition. The application in preparation of the antihypertensive medicines specifically comprises the application of the salviae miltiorrhizae and panax notoginseng composition as the antihypertensive medicines and the antihypertensive medicines comprising the salviae miltiorrhizae and panax notoginseng composition. The preparation method comprises the following steps: (1) extracting panax notoginseng saponins; (2) preparing salviae miltiorrhizae extract powder; and (3) mixing the panax notoginseng saponins extracted in the step (1) with the salviae miltiorrhizae extract powder prepared in the step (2), adding auxiliary materials to prepare the finished product. The salviae miltiorrhizae and panax notoginseng composition disclosed by the invention has the advantages of stable curative effect and no toxic or side effect as a pure traditional Chinese medicine preparation; the effective components in the traditional Chinese medicine are extracted from original plant cells in the preparation method; absorption and digestion of a patient on the medicine are facilitated; the medicine acting time is shortened; and the salviae miltiorrhizae and panax notoginseng composition can be relatively well applied to the antihypertensive medicines and the medicines with other efficacies.
Description
Technical field
The present invention relates to a kind of application and preparation method of red seven compositions, relate in particular to a kind of red seven compositions hypotensive in preparationApplication in medicine and preparation method.
Background technology
The main component of DANQI PIAN is the red sage root, pseudo-ginseng, and prescription derives from the drug standards-Traditional Chinese medicine historical preparation standard 1989. RedEffect of seven is promoting blood circulation and removing blood stasis, for stagnation of QI and blood, and cardiodynia, dizziness and headache, bellyache in menstrual period; Other indication asIrregular menstruation, postpartum stasis blocking underbelly pain etc., also can treat with DANQI PIAN. In addition, in the alleged coronary heart disease of doctor trained in Western medicine, heart strandBitterly, the blood stasis type person of levying such as hypertension, also can utilize DANQI PIAN supplemental treatment blood stasis symptom.
The preparation method that DANQI PIAN is recorded in first of Drug Standard of Ministry of Public Health of the Peoples Republic of China Traditional Chinese medicine historical preparation is: get threeSeven 150g, red sage root 150g, Radix Notoginseng powder is broken into fine powder, sieves; Red sage root boiling three times, collecting decoction, filters, and filtrate subtractsPressure is concentrated into relative density 1.351～.40's (50 DEG C)) thick paste, mix with above-mentioned Notoginseng Root, granulation, is pressed into 600Sheet, sugar coating, to obtain final product.
Documents 1:CN100389789C discloses a kind of preparation method of capsule containing red sage root and notoginseng, comprises step: (1) takes requiredThe red sage root, boiling 3 times, each 1 hour, add 8 times to the water of red sage root weight, merge extract, sieve, filtrate decompressionBe concentrated into relative density and be the Chilly cream of 1.35-1.40, for subsequent use; (2) by being broken into fine powder with the Radix Notoginseng powder of the weight such as the red sage root, sieve,For subsequent use; (3) get pseudo-ginseng fine powder and red sage root Chilly cream mixes, dry, pulverize, incapsulate, obtain capsule containing red sage root and notoginseng.
Documents 2:CN1679677A discloses one and has been used for the treatment of stagnation of QI and blood, ambition fraud pain, dizziness and headache, menstrual period abdomenThe pharmaceutical composition DANQI DIWAN of the symptoms such as pain, taking salviamiltiorrhizabung, pseudo-ginseng as raw material, together with a certain proportion of pharmaceutically suitable carrierBe prepared from.
In above-mentioned prior art, red seven preparations such as disclosed DANQI PIAN/capsule containing red sage root and notoginseng or DANQI DIWAN are all taking the red sage root as main ingredient, with pseudo-ginsengFor adjuvant is with treatment stagnation of QI and blood disease. Wherein:
The red sage root is called red ginseng, mountain ginseng, and radix salviae miltiorrhizae, red, red warm medicine, purple Radix Codonopsis, red ginseng, blood ginseng etc., property hardship, is slightly cold,The thoughts of returning home, Liver Channel. Effect has: promoting blood circulation for regulating menstruation, stasis-dispelling and pain-killing, the cool blood carbuncle that disappears, the relieving restlessness that clears away heart-fire, nourishing blood and tranquilization; Can be used for treatmentIrregular menstruation, through closing dysmenorrhoea, a lump in the abdomen causing distension and pain, chest ventral spine pain, hot numbness pain, sore swells and ache, dysphoria and insomnia; Hepatosplenomegaly,Angina pectoris. In " book on Chinese herbal medicine is newly organized ", record: the red sage root, bitter, gas is slightly cold, nontoxic; Enter the heart, spleen two warps; Specially menstruation regulating arteries and veins, reason boneMuscle is ached, and raw new blood, removes extravesated blood, the stillborn foetus that falls, and peaceful tire, the broken disease heavily fortified point that gathers, hemostasis is collapsed under band; The soft energy of pin numbness is strong, and eye is redSwollen can disappearing.
Pseudo-ginseng, because branch divides three, leaf is seven, therefore be called pseudo-ginseng, has another name called pseudo-ginseng, invaluable. Excavate in two seasons of winter in spring because being everlasting,Be divided into again " spring seven " and " winter seven ". Pseudo-ginseng is famous and precious Chinese medicine, as far back as the Ming Dynasty, and a famous medicine " book on Chinese herbal medicine that Li Shizhen (1518-1593 A.D.) is shownDetailed outline " both on the books. In Qing Dynasty's supplementary Amplifications of the Compendium of Materia Medica one book, also have " ginseng qi-tonifying first and third 7 enriches blood first "Record. Pseudo-ginseng has good hemostasia effect, can obviously shorten the hemorrhage and clotting time. Pseudo-ginseng can promote all kinds of haemocyte divisionsGrowth, increase number, have remarkable nourishing blood function. That pseudo-ginseng has is promoting blood circulation and removing blood stasis, the obvious curative effects of eliminate blood stasis and promote tissue regeneration.
Therefore, above-mentioned red seven composite preparations of the prior art are at stagnation of QI and blood, cardiodynia, dizziness and headache, bellyache in menstrual periodThere is good curative effect, but not yet have its application report aspect abrupt antihypertensive therapy.
Summary of the invention
The problem to be solved in the present invention is to provide a kind of application of red seven compositions, specifically in the application of preparing in blood-pressure drug;And provide a kind of preparation method of red seven compositions. Specifically comprise red seven composition conducts in the application of preparing in blood-pressure drugA kind of application of blood-pressure drug and a kind of blood-pressure drug that comprises these pellet seven compositions; Preparation method be a kind of taking pseudo-ginseng asRaw material, refluxing extraction makes arasaponin; Taking the red sage root as raw material, refluxing extraction makes Radix Salviae Miltiorrhizae extractum powder, then by three simultaneouslySeven total saponin(es and the mixing of Radix Salviae Miltiorrhizae extractum powder add auxiliary material to make the method for red seven compositions.
In order to solve the problems of the technologies described above, the present invention by the following technical solutions:
Provide a kind of red seven compositions in the application of preparing in blood-pressure drug, described red seven compositions taking salviamiltiorrhizabung, pseudo-ginseng asPrimary raw material is made.
The present invention also provides a kind of blood-pressure drug, comprises red seven compositions, and described red seven compositions comprise raw material pseudo-ginseng and with threeThe red sage root of seven equivalent.
The present invention also provides a kind of preparation method of red seven compositions, specifically comprises the following steps:
(1) extract arasaponin: take required pseudo-ginseng, Radix Notoginseng powder be broken to meal, with 10-12 doubly to the matter of three seven weightThe ethanolic solution heating and refluxing extraction that amount percentage concentration is 70-80% 3-4 time, each 1.8-2.2h, merges ethanol extract; WillEthanol extract reclaims ethanol and is concentrated into the pseudo-ginseng thick paste that relative density is 1.1-1.3, pseudo-ginseng thick paste is added on processed good largeOn macroporous adsorbent resin, first, with pure water washing, water lotion discards, then uses ethanolic solution wash-out, collects ethanol eluate, reclaims secondAlcohol is evaporated to thick paste, is dried to obtain arasaponin, for subsequent use;
Described relative density is the relative density value at 50 DEG C;
(2) prepare Radix Salviae Miltiorrhizae extractum powder: take and the red sage root of pseudo-ginseng equivalent, doubly measure in the quality percentage of red sage root weight dense with 8-10The ethanolic solution heating and refluxing extraction that degree is 70-80% 1-2 time, each 1.8-2.2h, obtains ethanol extract; Then ethanol is carriedThe dregs of a decoction after getting are doubly measured in the water heating and refluxing extraction of red sage root weight 1-2 time with 8-10 again, obtain aqueous extract;
Ethanol extract is reclaimed to ethanol and be concentrated into the red sage root thick paste one that relative density is 1.2-1.4; By aqueous extract Vacuum ConcentrationTo the relative density red sage root thick paste two that is 1.2-1.4; Merge thick paste one, two, thick paste is dried, pulverizes and to obtain Radix Salviae Miltiorrhizae extractum powder;
Described relative density is all the relative density values at 50 DEG C;
(3) arasaponin extracting in step (1) is mixed with the Radix Salviae Miltiorrhizae extractum powder of preparation in step (2), add auxiliary materialMake finished product.
Further, described step specifically comprises the following steps:
(1) extract arasaponin: take pseudo-ginseng 250g, Radix Notoginseng powder be broken to meal, with 10 times to the quality of three seven weightPercentage concentration is the ethanolic solution heating and refluxing extraction 3 times of 70-80%, and each 2h, merges ethanol extract, by ethanol extractReclaiming ethanol, to be concentrated into relative density be 1.2 pseudo-ginseng thick paste, pseudo-ginseng thick paste is added on processed good macroporous absorbent resin,First, with pure water washing, water lotion discards, then the ethanolic solution wash-out that is 80% by mass percentage concentration, collects corresponding ethanol and washesDe-liquid, ethanol eluate reclaims ethanol and is evaporated to thick paste, is dried to obtain arasaponin, for subsequent use;
Described relative density is the relative density value at 50 DEG C;
(2) prepare Radix Salviae Miltiorrhizae extractum powder: take red sage root 250g, measuring in the mass percentage concentration of red sage root weight with 8 times is 70-80%Ethanolic solution heating and refluxing extraction 1 time, each 2h, obtains ethanol extract; Then the dregs of a decoction after alcohol extract are used to 8 times againMeasure in the water heating and refluxing extraction of red sage root weight 1 time, obtain aqueous extract;
Ethanol extract is reclaimed to ethanol, and to be concentrated into relative density be 1.3 red sage root thick paste one; By aqueous extract Vacuum Concentration to phaseThe red sage root thick paste two that is 1.3 to density; Merge thick paste one, two, thick paste is dried, pulverizes and to obtain Radix Salviae Miltiorrhizae extractum powder;
Described relative density is all the relative density values at 50 DEG C;
(3) arasaponin extracting in step (1) is mixed with the Radix Salviae Miltiorrhizae extractum powder of preparation in step (2), add auxiliary materialMake finished product.
Preferably, in above-mentioned preparation method:
In step (1), the pseudo-ginseng thick paste being added on processed good macroporous absorbent resin is first washed with pure water, water lotion discards,Be respectively successively again 60%, 70%, 80% ethanolic solution wash-out by mass percentage concentration, merge ethanol eluate, ethanol is washedDe-liquid reclaims ethanol, spraying dry arasaponin or ethanol eluate is reclaimed to ethanol, vacuum drying is also pulverized to obtain pseudo-ginsengTotal saponin(e.
Preferably,
Adopt in step (2) the dry or heated-air drying of vacuum drying or spraying or freeze drying to make Radix Salviae Miltiorrhizae extractum powder.
Further, therein in an embodiment,
In described step (3), add auxiliary material to granulate dry, in flakes, sugar coating or film-coating obtain tablet in compacting;
Described auxiliary material comprises: sodium carboxymethyl starch, microcrystalline cellulose, dolomol.
Further, in another embodiment,
In described step (3), add auxiliary material to make to incapsulate shell after content filler and make capsule or soft capsule;
Or add auxiliary material to make dripping pill in described step (3).
Pellet seven compositions prepared by above-mentioned preparation method not only can be applied in the preparation of blood-pressure drug, can also be applied to pelletIn the preparation of the medicine of seven composition other treatment effects.
Described red seven compositions comprise DANQI PIAN, capsule containing red sage root and notoginseng, soft capsule of red sage root and notoginseng or DANQI DIWAN.
In the present invention, the hypotensive mechanism of action of each raw material components is as follows:
Many factors can cause elevation of the blood pressure. A kind of factor is because cardiac pumping ability is strengthened (as cardiac contractile force increasesDeng), making to pump each second blood increases. A kind of factor is that main artery has lost normal elasticity, becomes stiff, when heart pumps bloodWhen liquid, can not effectively expand, therefore, the blood flow that each heartbeat pumps, by than normal narrow space, causes pressure to raise.This is also that hypertension mostly occurs and causes arterial wall to thicken and become stiff the elderly's reason in atherosclerotic, and main artery losesGo normal elasticity, major part is to lead due to the inner membrance of blood vessel and flesh layer thickening, collagen, elastin laminin, lipid and calcium content increaseCause. Another kind of factor is that whole body parteriole can temporary contraction equally also cause blood due to the stimulation of hormone in neural and bloodThat presses increases.
Antihypertensive, approximately can divide several from site of action and the mechanism of action: diuretics, Re-A-ASystem depressant, calcium channel blocker, adrenoceptor blocking drug, sympathicolytic and blood vessel expansion medicine.
Pellet seven compositions in the present invention are taking salviamiltiorrhizabung, pseudo-ginseng as primary raw material, wherein:
1, pseudo-ginseng: have another name called pseudo-ginseng, Chinese medicine pseudo-ginseng is using its root as medicinal part, has the hemostasis of the loose stasis of blood, detumescence ding-tong itEffect. Cure mainly spitting of blood, spit blood, bleeding from five sense organs or subcutaneous tissue, has blood in stool, uterine bleeding, and traumatism and bleeding, chest ventral spine pain, falling falls forward swells and ache.
Active ingredient in pseudo-ginseng comprises: 24 kinds of notoginsenosides, account for 9.75%～14.90% of total amount, and be mainly ginsenosideRb1, Rd, Re, Rgl, Rg2, Rhl and notoginsenoside R, R2, R3, R4, R6, R7; 77 kinds of volatile oil; 17 kinds of ammoniaThe several physiological active substances such as base acid and notoginseng polysaccharide, pseudo-ginseng flavones. In addition containing styptic activity composition pseudo-ginseng propylhomoserin, a small amount ofFlavonoid glycoside, starch, protein, grease, Quercetin, cupreol, notoginseng polysaccharide and calcium, iron, copper, chromium, manganese, zinc etc.Various trace elements, and have alkaloid reaction.
Arasaponin is the main active ingredient of pseudo-ginseng, mainly comprises ginsenoside Rb1, ginsenoside Rg1, notoginsenosideR1 etc. Main effect: promoting blood circulation, promote blood circulation active. Arasaponin is built up and is sticked by promoting blood circulation, inhibition blood platelet,Reach cleaning blood environment, the object purifying the blood.
Find after deliberation: treat hypertension with arasaponin, treat after 20 days, can obviously reduce the blood pressure increasing can also be obviousReducing heart rate, result shows that arasaponin can significantly reduce hyperpietic MDA, obviously increased SOD, increases RBC deformationAbility, reduces erythrocytic aggregation. Pseudo-ginseng is expanded blood vessel, hypotensive activity mainly and resistance Ca2+Interior stream is relevant, three in pseudo-ginsengSeven total saponin(es (PNS) have definite cardiovascular pharmacological activity, can block specifically acceptor dependence calcium on vascular smooth musclePassage, reduces Ca2+Interior stream, also can obviously reduce the Ca that norepinephrine causes2+Interior stream.
2, the red sage root: have another name called red ginseng, radix salviae miltiorrhizae, red etc., salviamiltiorrhizabung, taking its root or rhizome as by part, has and invigorates blood circulationThe stasis of blood of dispelling, inducing meastruation to relieve menalgia, the relieving restlessness that clears away heart-fire, disappear effect of carbuncle of cool blood. For chest impediment and cardialgia, gastral cavity abdomen hypochondriac pain, lump in the abdomen lump in the abdomen is gathered, hot numbnessPain, dysphoria and insomnia, irregular menstruation, dysmenorrhoea is through closing, and sore swells and ache.
Red sage root master is containing fat-soluble Diterpenoids from bulbus and water miscible phenolic acid composition, also containing flavonoids, triterpenes, sterol etc. itsHis composition. In liposoluble constituent, belong to having of quinone, ketone type structure: tanshinone, Cryptotanshinone, isotanshinone, different Cryptotanshinone,Hydroxyl tanshinone, saivianic acid A acid etc. Water miscible phenol acid compound has: Salvianic acidA, B, C; Salviandic acid A, B, C,D, E, G; Rosmarinic acid, methyl rosmarinate, alkannic acid mono methyl ester, alkannic acid dimethyl ester, alkannic acid ethyl ester, alkannic acid B,Protocatechualdehyde, caffeic acid, isoferulic acid etc.
Danshinolic acid is most important part in red sage root water soluble ingredient, and danshinolic acid class material all has similar basic structure,And there is similar pharmacological action. In danshinolic acid class material, the activity of salviandic acid A and tanshin polyphenolic acid B is the strongest, has control artery hardChange, the effect such as anti-oxidant.
Tanshinone is the chief component in fat soluble ingredient of red sage root, is generally ether or ethanol extract, all contain phase quinone orThe structure of paraquinones, general name tanshinone compound, shows multiple biologically active. Numerous research shows, tanshinone compoundThere is hemangiectasis aspect cardiovascular, improve microcirculation, suppress the effects such as platelet aggregation and antithrombotic formation, and can pass throughRemove oxygen radical, alleviate calcium overload, improve the approach such as energetic supersession and protect Myocardial Ischemia-reperfusion.
The red sage root has the myocardial contractive power of reinforcement, improves cardiac function, does not increase MCO; To blood vessel function coronary artery dilating,Increase MBF; Expansion peripheral vascular, blood flow increases; Cerebral blood flow (CBF) declines; Antithrombotic forms and improves plasmin activity;Extend, the clotting time; Suppress platelet aggregation (improving cAMP level inhibition TXA2 in blood platelet synthesizes); Improve blood flowBecome effects such as learning characteristic (blood viscosity reduction, erythrocyte electrophoretic time shorten).
Beneficial effect of the present invention is as follows:
1, the present invention finds that by clinical testing red seven compositions, to good treatment and the prevention effect of having reduced blood pressure, can applyIn preparing blood-pressure drug.
2, in existing the Sanitation Ministry medicine standard record and the disclosed preparation method about DANQI PIAN of prior art, be all directAdopt the powder after pseudo-ginseng is pulverized to be directly used as medicine, effect of every kind of active ingredient in pseudo-ginseng is not quite similar. And preparation of the present inventionIn method, adopt reflux extraction, effective component extracting arasaponin from pseudo-ginseng, makes to contain purity more in red seven compositionsHigh arasaponin, thus make effect of its promoting blood circulation more remarkable, and find after deliberation: arasaponin has obviouslyThe effect that can reduce blood pressure, pellet seven compositions that therefore can make to make can be applied to better prepares blood-pressure drug.
In the preparation method of pellet seven preparations of 3, recording in prior art, or directly only adopt decocting to boil, extract having in the red sage rootEffect composition, or adopt the active ingredient in the alcohol extract red sage root, it is mainly the water-soluble effective one-tenth in the red sage root that decocting boils what obtainPoint, be the fat-soluble active ingredient in the red sage root and alcohol extract mainly extracts, in pellet seven composite preparations that therefore makeComposition is also different, and because the major function of the aqueous soluble active constituent in the red sage root and liposoluble constituent is not quite similar, therefore itsEffect is also different. In preparation method of the present invention, first adopt the liposoluble constituent in the ethanolic solution refluxing extraction red sage root, then adoptWater extraction is got the water soluble ingredient in the red sage root, make to contain in the active ingredient of red seven compositions simultaneously abundanter liposoluble constituent andWater soluble ingredient not only has better effect in the treatment reducing blood pressure, and also can make otherwise effect more remarkable.
In preparation method of the present invention, adopt the liposoluble constituent in the ethanolic solution refluxing extraction red sage root, be mainly tanshinone,Adopt the water soluble ingredient in the extraction with aqueous solution red sage root, be mainly danshinolic acid.
4, while adopting reflux extraction to prepare the extract of each composition, adopt water as solvent, economy is easy to get, and polarity is large, dissolvesScope is wide; And adopt ethanol as solvent because ethanol is semi-polarity solvent, dissolubility between polarity and non-polar solven,The solubility of various Chinese medicine chemical compositions in ethanol changes with the concentration of ethanol, and ethanol has certain pharmacological action, butThat price is more expensive. The present invention gets and alcohol extract in conjunction with water extraction, not only can comprehensively obtain water-soluble in Chinese medicine pseudo-ginseng and the red sage rootThe fat-soluble active ingredient that active ingredient can also obtain containing in medicine, better efficacy, simultaneously also more economical.
5, red seven compositions are pure Chinese medicinal preparation, are applied in abrupt antihypertensive therapy, compare Western medicine, although do not have the speed of Western medicine fast,But curative effect is stable, because its effect is many target spots, in step-down, can also take into account hypertensive other pathology links,There is the microcirculation of improvement, lipopenicillinase is anti-oxidant, protection endothelium, regulates the effect such as vaso-active substance, and compares nontoxic secondary work of Western medicineWith, in obviously improving hypertensive clinical symptoms, can also improve patient's quality of life. Red seven compositions are as onePure Chinese medicinal preparation has too curative effect stable, the feature having no side effect in activating blood and removing stasis drug.
6, in the preparation method of red seven compositions of the present invention, adopt respectively reflux extraction to extract in traditional Chinese medicine ingredients pseudo-ginseng, the red sage rootActive ingredient extracts effective ingredient in former plant cell, is more beneficial to patient to the assimilating of medicine, contractingThe short drug effect time, make the curative effect of medicine better.
Detailed description of the invention
Below in conjunction with embodiment, the present invention is further described, but be not used for limiting the scope of the invention.
Embodiment 1
A kind of red seven compositions of the present embodiment, are specially a kind of DANQI PIAN, and it makes by the following method:
(1) extract arasaponin: take pseudo-ginseng 250g, Radix Notoginseng powder be broken to meal, with 10 times to the quality of three seven weightPercentage concentration is 75% ethanolic solution heating and refluxing extraction 3 times, and each 2h, merges ethanol extract, and ethanol extract is returnedReceiving ethanol, to be concentrated into relative density be 1.2 pseudo-ginseng thick paste, and pseudo-ginseng thick paste is added on processed good macroporous absorbent resin, rightThe pseudo-ginseng thick paste being added on processed good macroporous absorbent resin first washs with pure water, and water lotion discards, then uses successively quality percentageConcentration is respectively 60%, 70%, 80% ethanolic solution wash-out, merges ethanol eluate, and ethanol eluate is reclaimed to ethanol, subtractsPressure is concentrated into thick paste, and spraying is dried to obtain arasaponin, for subsequent use;
Described relative density is the relative density value at 50 DEG C;
(2) prepare Radix Salviae Miltiorrhizae extractum powder: take red sage root 250g, by 8 times of second that to measure in the mass percentage concentration of red sage root weight be 75%Alcoholic solution heating and refluxing extraction 1 time, each 2h, obtains ethanol extract; Then by the dregs of a decoction after alcohol extract again with 8 times measure inThe water heating and refluxing extraction of red sage root weight 1 time, obtains aqueous extract;
Ethanol extract is reclaimed to ethanol, and to be concentrated into relative density be 1.3 red sage root thick paste one; By aqueous extract Vacuum Concentration to phaseThe red sage root thick paste two that is 1.3 to density; Merge thick paste one, two, by thick paste vacuum drying, pulverize to obtain Radix Salviae Miltiorrhizae extractum powder;
Described relative density is all the relative density values at 50 DEG C;
(3) arasaponin extracting in step (1) is mixed with the Radix Salviae Miltiorrhizae extractum powder of preparation in step (2), add auxiliary materialGranulate dry, be pressed into 1000, every is 0.3g, and sugar coating or film-coating obtain tablet;
Described auxiliary material comprises sodium carboxymethyl starch, microcrystalline cellulose, dolomol.
Embodiment 2
A kind of red seven compositions of the present embodiment, are specially a kind of capsule containing red sage root and notoginseng or soft capsule, and it makes by the following method:
(1) extract arasaponin: take pseudo-ginseng 250g, Radix Notoginseng powder be broken to meal, with 10 times to the quality of three seven weightPercentage concentration is 70% ethanolic solution heating and refluxing extraction 4 times, and each 1.8h, merges ethanol extract, by ethanol extractReclaiming ethanol, to be concentrated into relative density be 1.1 pseudo-ginseng thick paste, pseudo-ginseng thick paste is added on processed good macroporous absorbent resin,The pseudo-ginseng thick paste being added on processed good macroporous absorbent resin is first washed with pure water, and water lotion discards, then uses quality percentage denseDegree is 80% ethanolic solution wash-out, collects ethanol eluate, reclaims ethanol and is evaporated to thick paste, and vacuum drying is also pulverizedArasaponin, for subsequent use;
Described relative density is the relative density value at 50 DEG C;
(2) prepare Radix Salviae Miltiorrhizae extractum powder: take red sage root 250g, by 8 times of second that to measure in the mass percentage concentration of red sage root weight be 75%Alcoholic solution heating and refluxing extraction 2 times, each 1.8h, obtains ethanol extract; Then the dregs of a decoction after alcohol extract are used again to 8 times of amountsIn the water heating and refluxing extraction of red sage root weight 1 time, obtain aqueous extract;
Ethanol extract is reclaimed to ethanol, and to be concentrated into relative density be 1.2 red sage root thick paste one; By aqueous extract Vacuum Concentration to phaseThe red sage root thick paste two that is 1.2 to density; Merge thick paste one, two, thick paste spraying is dried to obtain to Radix Salviae Miltiorrhizae extractum powder;
Described relative density is all the relative density values at 50 DEG C;
(3) arasaponin extracting in step (1) is mixed with the Radix Salviae Miltiorrhizae extractum powder of preparation in step (2), add auxiliary materialMake and incapsulate shell after content filler and make capsule or soft capsule;
The quality of the content filler of described every seed lac wafer is 0.3g. Capsule is faster than tablet in GI disintegration time, and oneAs 5～10 minutes, and little to GI irritation, be not easy gastric mucosa to produce damage, therefore for stomach absorption function notVery good patient, can select to take capsule.
Embodiment 3
A kind of red seven compositions of the present embodiment, are specially a kind of DANQI DIWAN, and it makes by the following method:
(1) extract arasaponin: take pseudo-ginseng 250g, Radix Notoginseng powder be broken to meal, with 12 times to the quality of three seven weightPercentage concentration is 80% ethanolic solution heating and refluxing extraction 3 times, and each 2.2h, merges ethanol extract, by ethanol extractReclaiming ethanol, to be concentrated into relative density be 1.3 pseudo-ginseng thick paste, pseudo-ginseng thick paste is added on processed good macroporous absorbent resin,The pseudo-ginseng thick paste being added on processed good macroporous absorbent resin is first washed with pure water, and water lotion discards, then uses successively quality hundredPoint concentration is respectively 60%, 70%, 80% ethanolic solution wash-out, merges ethanol eluate, and reclaim ethanol and be evaporated to thick paste,Vacuum drying is also pulverized to obtain arasaponin, for subsequent use;
Described relative density is the relative density value at 50 DEG C;
(2) prepare Radix Salviae Miltiorrhizae extractum powder: take red sage root 250g, to measure in the mass percentage concentration of red sage root weight be 80% with 10 timesEthanolic solution heating and refluxing extraction 1 time, each 2.2h, obtains ethanol extract; Then the dregs of a decoction after alcohol extract are used to 10 againDoubly measure in the water heating and refluxing extraction of red sage root weight 1 time, obtain aqueous extract;
Ethanol extract is reclaimed to ethanol, and to be concentrated into relative density be 1.4 red sage root thick paste one; By aqueous extract Vacuum Concentration to phaseThe red sage root thick paste two that is 1.4 to density; Merge thick paste one, two, thick paste heated-air drying is obtained to Radix Salviae Miltiorrhizae extractum powder;
Described relative density is all the relative density values at 50 DEG C;
(3) arasaponin extracting in step (1) is mixed with the Radix Salviae Miltiorrhizae extractum powder of preparation in step (2), add auxiliary materialMake DANQI DIWAN;
The infiltration rate of dropping pill formulation, bioavilability are also compared tablet and are wanted better.
The Application Example of pellet seven compositions in the present invention in blood-pressure drug treatment is as follows:
Application Example 1
Permitted so-and-so, man, 59 years old, people from Changsha, teacher, suffers from former through The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine's inspection in 2008Hair style hypertension (92/149mmHg), oral administration Nitrendipine Tablet treatment six months, coronary flow improves, and controlling of blood pressure exists88/145mmHg, after add in embodiment 1 DANQI PIAN 3 years, taking dose be one time 4, every day three times, after treatment,Blood pressure substantially improves and maintains 85/131mmHg.
Application Example 2
Explain so-and-so, man, 61 years old, Chenzhou, Hunan Province people, teacher, conscious dizziness in 2012, attached through Hunan University of Traditional Chinese Medicine firstExamination in hospital suffers from essential hypertension 93/152mmg, because abstaining from the side effect of chemical antihypertensive medicine, recommends to take DANQI PIAN, clothesWith dosage be one time 4, every day three times, after treating 1 year, subjective symptoms is improved, and within 2013, recovers normal through health check-up blood pressure(81/127mmHg)。
Application Example 3
Luo, man, 55 years old, people from Changsha, in October, 2011, consciously uncomfortable in chestly breathed hard, weak, sleep bad, warpThe Third Xiangya Hospital of Central South University's inspection, electrocardiogram and B ultrasonic show to suffer from coronary heart disease, and blood supply insufficiency of brain, blood pressure 93/145mmHgThree courses for the treatment of of capsule containing red sage root and notoginseng are taken in recommendation, one time 4, every day three times, after treatment, conscious above-mentioned symptom disappears, blood pressure82/132mmHg, and sleep quality improves completely.
Application Example 4
Zhang, man, 58 years old, people from Changsha, check to suffer from coronary heart disease through The Third Xiangya Hospital of Central South University in December, 2011,Blood pressure 95/145mmHg, recommends to take three courses for the treatment of of DANQI DIWAN, and conscious above-mentioned symptom disappears, blood pressure 83/135mmHg, and sleepDormancy quality is improved completely.
Above-mentioned Application Example shows, notoginseng composition preparation of the present invention is for the comparatively significantly result for the treatment of that reduced blood pressure,Compare chemical antihypertensive medicine, the present invention is pure Chinese medicinal preparation, has advantages of and has no side effect; And notoginseng composition of the present inventionIn contain the pseudo-ginseng that the purity that extracts through circumfluence method is higher with content active ingredient arasaponin and the red sage root in effective becomeDivide tanshinone (liposoluble constituent) and danshinolic acid (water soluble ingredient), to the good auxiliary therapeutic action that reduced blood pressure, andCurative effect is stable; And in preparation method, adopt reflux extraction that effective ingredient is extracted in former plant cell,More be beneficial to patient to the assimilating of medicine, shorten the drug effect time, therefore curative effect is better.
Above-described embodiment is to further illustrate of the present invention, instead of limits the scope of the invention. Do not depart from of the present invention wholeTechnical scope, can carry out various amendments and change.
Claims (10)
1. pellet seven compositions are in an application of preparing in blood-pressure drug, and described red seven compositions are taking salviamiltiorrhizabung, pseudo-ginseng as mainWant raw material to make.
2. a kind of red seven compositions according to claim 1, in the application of preparing in blood-pressure drug, is characterized in that,
The preparation method of described red seven compositions is:
(1) extract arasaponin: take required pseudo-ginseng, Radix Notoginseng powder be broken to meal, with 10-12 doubly to the matter of three seven weightThe ethanolic solution heating and refluxing extraction that amount percentage concentration is 70-80% 3-4 time, each 1.8-2.2h, merges ethanol extract; WillEthanol extract reclaims ethanol and is concentrated into the pseudo-ginseng thick paste that relative density is 1.1-1.3, pseudo-ginseng thick paste is added on processed good largeOn macroporous adsorbent resin, first, with pure water washing, water lotion discards, then uses ethanolic solution wash-out, collects ethanol eluate, reclaims secondAlcohol is evaporated to thick paste, is dried to obtain arasaponin, for subsequent use;
Described relative density is the relative density value at 50 DEG C;
(2) prepare Radix Salviae Miltiorrhizae extractum powder: take and the red sage root of pseudo-ginseng equivalent, doubly measure in the quality percentage of red sage root weight dense with 8-10The ethanolic solution heating and refluxing extraction that degree is 70-80% 1-2 time, each 1.8-2.2h, obtains ethanol extract; Then ethanol is carriedThe dregs of a decoction after getting are doubly measured in the water heating and refluxing extraction of red sage root weight 1-2 time with 8-10 again, obtain aqueous extract;
Ethanol extract is reclaimed to ethanol and be concentrated into the red sage root thick paste one that relative density is 1.2-1.4; By aqueous extract Vacuum ConcentrationTo the relative density red sage root thick paste two that is 1.2-1.4; Merge thick paste one, two, thick paste is dried, pulverizes and to obtain Radix Salviae Miltiorrhizae extractum powder;
Described relative density is all the relative density values at 50 DEG C;
(3) arasaponin extracting in step (1) is mixed with the Radix Salviae Miltiorrhizae extractum powder of preparation in step (2), add auxiliary materialMake finished product.
3. a kind of red seven compositions according to claim 2, in the application of preparing in blood-pressure drug, is characterized in that,
The preparation method of described red seven compositions, specifically comprises the following steps:
(1) extract arasaponin: take pseudo-ginseng 250g, Radix Notoginseng powder be broken to meal, with 10 times to the quality of three seven weightPercentage concentration is the ethanolic solution heating and refluxing extraction 3 times of 70-80%, and each 2h, merges ethanol extract, by ethanol extractReclaiming ethanol, to be concentrated into relative density be 1.2 pseudo-ginseng thick paste, pseudo-ginseng thick paste is added on processed good macroporous absorbent resin,First, with pure water washing, water lotion discards, then the ethanolic solution wash-out that is 80% by mass percentage concentration, collects corresponding ethanol and washesDe-liquid, ethanol eluate reclaims ethanol and is evaporated to thick paste, is dried to obtain arasaponin, for subsequent use;
Described relative density is the relative density value at 50 DEG C;
(2) prepare Radix Salviae Miltiorrhizae extractum powder: take red sage root 250g, measuring in the mass percentage concentration of red sage root weight with 8 times is 70-80%Ethanolic solution heating and refluxing extraction 1 time, each 2h, obtains ethanol extract; Then the dregs of a decoction after alcohol extract are used to 8 times againMeasure in the water heating and refluxing extraction of red sage root weight 1 time, obtain aqueous extract;
Ethanol extract is reclaimed to ethanol, and to be concentrated into relative density be 1.3 red sage root thick paste one; By aqueous extract Vacuum Concentration to phaseThe red sage root thick paste two that is 1.3 to density; Merge thick paste one, two, thick paste is dried, pulverizes and to obtain Radix Salviae Miltiorrhizae extractum powder;
Described relative density is all the relative density values at 50 DEG C;
(3) arasaponin extracting in step (1) is mixed with the Radix Salviae Miltiorrhizae extractum powder of preparation in step (2), add auxiliary materialMake finished product.
4. a blood-pressure drug, comprises red seven compositions, it is characterized in that,
Described red seven compositions comprise raw material pseudo-ginseng and the red sage root with pseudo-ginseng equivalent.
5. a preparation method for pellet seven compositions, is characterized in that,
Specifically comprise the following steps:
(1) extract arasaponin: take required pseudo-ginseng, Radix Notoginseng powder be broken to meal, with 10-12 doubly to the matter of three seven weightThe ethanolic solution heating and refluxing extraction that amount percentage concentration is 70-80% 3-4 time, each 1.8-2.2h, merges ethanol extract; WillEthanol extract reclaims ethanol and is concentrated into the pseudo-ginseng thick paste that relative density is 1.1-1.3, pseudo-ginseng thick paste is added on processed good largeOn macroporous adsorbent resin, first, with pure water washing, water lotion discards, then uses ethanolic solution wash-out, collects ethanol eluate, reclaims secondAlcohol is evaporated to thick paste, is dried to obtain arasaponin, for subsequent use;
Described relative density is the relative density value at 50 DEG C;
(2) prepare Radix Salviae Miltiorrhizae extractum powder: take and the red sage root of pseudo-ginseng equivalent, doubly measure in the quality percentage of red sage root weight dense with 8-10The ethanolic solution heating and refluxing extraction that degree is 70-80% 1-2 time, each 1.8-2.2h, obtains ethanol extract; Then ethanol is carriedThe dregs of a decoction after getting are doubly measured in the water heating and refluxing extraction of red sage root weight 1-2 time with 8-10 again, obtain aqueous extract;
Ethanol extract is reclaimed to ethanol and be concentrated into the red sage root thick paste one that relative density is 1.2-1.4; By aqueous extract Vacuum ConcentrationTo the relative density red sage root thick paste two that is 1.2-1.4; Merge thick paste one, two, thick paste is dried, pulverizes and to obtain Radix Salviae Miltiorrhizae extractum powder;
Described relative density is all the relative density values at 50 DEG C;
(3) arasaponin extracting in step (1) is mixed with the Radix Salviae Miltiorrhizae extractum powder of preparation in step (2), add auxiliary materialMake finished product.
6. the preparation method of a kind of red seven compositions according to claim 5, is characterized in that,
Specifically comprise the following steps:
(1) extract arasaponin: take pseudo-ginseng 250g, Radix Notoginseng powder be broken to meal, with 10 times to the quality of three seven weightPercentage concentration is the ethanolic solution heating and refluxing extraction 3 times of 70-80%, and each 2h, merges ethanol extract, by ethanol extractReclaiming ethanol, to be concentrated into relative density be 1.2 pseudo-ginseng thick paste, pseudo-ginseng thick paste is added on processed good macroporous absorbent resin,First, with pure water washing, water lotion discards, then the ethanolic solution wash-out that is 80% by mass percentage concentration, collects corresponding ethanol and washesDe-liquid, ethanol eluate reclaims ethanol and is evaporated to thick paste, is dried to obtain arasaponin, for subsequent use;
Described relative density is the relative density value at 50 DEG C;
(2) prepare Radix Salviae Miltiorrhizae extractum powder: take red sage root 250g, measuring in the mass percentage concentration of red sage root weight with 8 times is 70-80%Ethanolic solution heating and refluxing extraction 1 time, each 2h, obtains ethanol extract; Then the dregs of a decoction after alcohol extract are used to 8 times againMeasure in the water heating and refluxing extraction of red sage root weight 1 time, obtain aqueous extract;
Ethanol extract is reclaimed to ethanol, and to be concentrated into relative density be 1.3 red sage root thick paste one; By aqueous extract Vacuum Concentration to phaseThe red sage root thick paste two that is 1.3 to density; Merge thick paste one, two, thick paste is dried, pulverizes and to obtain Radix Salviae Miltiorrhizae extractum powder;
Described relative density is all the relative density values at 50 DEG C;
(3) arasaponin extracting in step (1) is mixed with the Radix Salviae Miltiorrhizae extractum powder of preparation in step (2), add auxiliary materialMake finished product.
7. according to the preparation method of a kind of red seven compositions described in claim 5 or 6, it is characterized in that,
In step (1), the pseudo-ginseng thick paste being added on processed good macroporous absorbent resin is first washed with pure water, water lotion discards,Be respectively successively again 60%, 70%, 80% ethanolic solution wash-out by mass percentage concentration, merge ethanol eluate, ethanol is washedDe-liquid reclaims ethanol and is evaporated to thick paste, spraying dry arasaponin or ethanol eluate is reclaimed to ethanol reduced pressure concentrationTo thick paste, vacuum drying is also pulverized to obtain arasaponin.
8. according to the preparation method of a kind of red seven compositions described in claim 5 or 6, it is characterized in that,
Adopt in step (2) the dry or heated-air drying of vacuum drying or spraying or freeze drying to make Radix Salviae Miltiorrhizae extractum powder.
According to a kind of red seven compositions described in claim 5 or 6 in the application of preparing in blood-pressure drug, it is characterized in that,
In described step (3), add auxiliary material to granulate dry, in flakes, sugar coating or film-coating obtain tablet in compacting;
Described auxiliary material comprises: sodium carboxymethyl starch, microcrystalline cellulose, dolomol.
10. according to the preparation method of a kind of red seven compositions described in claim 5 or 6, it is characterized in that,
In described step (3), add auxiliary material to make to incapsulate shell after content filler and make capsule or soft capsule;
Or add auxiliary material to make dripping pill in described step (3).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610163942.0A CN105596420A (en) | 2016-03-22 | 2016-03-22 | Application of salviae miltiorrhizae and panax notoginseng composition and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610163942.0A CN105596420A (en) | 2016-03-22 | 2016-03-22 | Application of salviae miltiorrhizae and panax notoginseng composition and preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105596420A true CN105596420A (en) | 2016-05-25 |
Family
ID=55977155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610163942.0A Pending CN105596420A (en) | 2016-03-22 | 2016-03-22 | Application of salviae miltiorrhizae and panax notoginseng composition and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105596420A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114470035A (en) * | 2022-03-23 | 2022-05-13 | 暨南大学 | A composition containing Chinese medicinal extract, its preparation method and application in preparing product with antioxidant effect |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1788749A (en) * | 2005-10-20 | 2006-06-21 | 北京汉典中西药研究开发中心 | Preparation method of capsule containing red sage root and notoginseng |
-
2016
- 2016-03-22 CN CN201610163942.0A patent/CN105596420A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1788749A (en) * | 2005-10-20 | 2006-06-21 | 北京汉典中西药研究开发中心 | Preparation method of capsule containing red sage root and notoginseng |
Non-Patent Citations (1)
| Title |
|---|
| 付超美: "《中国优秀博硕士学位论文全文数据库》", 1 April 2004 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114470035A (en) * | 2022-03-23 | 2022-05-13 | 暨南大学 | A composition containing Chinese medicinal extract, its preparation method and application in preparing product with antioxidant effect |
| CN114470035B (en) * | 2022-03-23 | 2023-02-21 | 暨南大学 | A composition containing Chinese medicinal extract, its preparation method and application in preparing product with antioxidant effect |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104645091A (en) | Capsule for treating hypertension | |
| CN101502588B (en) | Composition for beauty treatment and removing blain and method for preparing the same | |
| CN103961521A (en) | Traditional Chinese medicine composition for treating aplastic anemia and preparation method | |
| CN108578544A (en) | A kind of Chinese medicine composition and the preparation method and application thereof with blood sugar reducing function | |
| CN102225100A (en) | Chinese medicinal formulation for treating cardiovascular and cerebrovascular diseases and preparation process of products thereof | |
| CN103989970B (en) | A kind of Chinese medicine composition treating hypertension | |
| CN103830436A (en) | Traditional Chinese medicine composition for treating hypertension and preparation method thereof | |
| CN101856389A (en) | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and application thereof | |
| CN103919910A (en) | Medicine for treating coronary heart disease | |
| CN101099775B (en) | Cardiac and cerebral vascular disease treating medicine | |
| CN109731074A (en) | A kind of for oral administration and external application suit and preparation method thereof for alleviating asthenopia and xerophthalmia | |
| CN105395842A (en) | Traditional Chinese medicine composition for treating diabetes and oral preparation and preparation method thereof | |
| CN101884661A (en) | Traditional Chinese medical preparation containing leeches and astragalus and used for treating cardiovascular and cerebrovascular diseases | |
| CN105596420A (en) | Application of salviae miltiorrhizae and panax notoginseng composition and preparation method | |
| CN1970050B (en) | Pharmaceutical composition for treating arrhythmia and preparation process thereof | |
| CN105833055A (en) | Traditional Chinese medicine composition for treating hypertension, hyperlipidemia and hyperglycemia and preparing method and application thereof | |
| CN102008571B (en) | Traditional Chinese medicine composition as well as preparation method and application thereof | |
| CN105169149A (en) | Traditional Chinese medicine composition for treating pyrophlegm stasis accumulation type thyroid cancer, preparation method and application | |
| CN104524288A (en) | Traditional Chinese medicinal composition for treating hypertension | |
| CN103690834B (en) | A kind of blood pressure lowering Chinese medicinal composition and preparation method thereof | |
| CN103585366A (en) | Medicine for treating ischemic hyperlipidemia and preparation method thereof | |
| CN103768116A (en) | GMP (Good Manufacturing Practice) production technology and application method of pseudo-ginseng powder bag-steeping-type products | |
| CN114767816B (en) | Traditional Chinese medicine composition for treating coronary heart disease and preparation method thereof | |
| CN103239620B (en) | Traditional Chinese medicine for treating qi-deficiency heart diseases | |
| CN104547930A (en) | Heat-clearing and diuresis-promoting medicament for spleen-deficiency and dampness-heat type jaundice hepatitis and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160525 |
|
| RJ01 | Rejection of invention patent application after publication |